Cargando…

Simplified scoring of the Actionable 8-item screening questionnaire for neurogenic bladder overactivity in multiple sclerosis: a comparative analysis of test performance at different cut-off points

BACKGROUND: The Actionable questionnaire is an 8-item tool to screen patients with multiple sclerosis (MS) for neurogenic bladder problems, identifying those patients who might benefit from urological referral and bladder-specific treatment. The original scoring yields a total score of 0 to 24 with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jongen, Peter Joseph, Blok, Bertil F., Heesakkers, John P., Heerings, Marco, Lemmens, Wim A., Donders, Rogier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619527/ https://www.ncbi.nlm.nih.gov/pubmed/26498107 http://dx.doi.org/10.1186/s12894-015-0100-z

Ejemplares similares

Validation of a Dutch version of the Actionable 8-item screening questionnaire for neurogenic bladder overactivity in multiple sclerosis: an observational web-based study
por: Jongen, Peter Joseph, et al.
Publicado: (2015)

Real life persistence rate with antimuscarinic treatment in patients with idiopathic or neurogenic overactive bladder: a prospective cohort study with solifenacin
por: Tijnagel, Marloes J., et al.
Publicado: (2017)

A prospective web-based patient-centred interactive study of long-term disabilities, disabilities perception and health-related quality of life in patients with multiple sclerosis in The Netherlands: the Dutch Multiple Sclerosis Study protocol
por: Jongen, Peter Joseph, et al.
Publicado: (2015)

Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity
por: Tannenbaum, Stacey, et al.
Publicado: (2020)

Overactive Bladder: Pathophysiology, Diagnostics, and Therapies
por: Heesakkers, John P. F. A., et al.
Publicado: (2011)

Onabotulinum Toxin A (Botox®) in the Treatment of Neurogenic Bladder Overactivity
por: Rohrsted, Malene, et al.
Publicado: (2012)

Treatment of neurogenic detrusor overactivity and overactive bladder with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Nitti, Victor, et al.
Publicado: (2023)

Glatiramer acetate treatment persistence - but not adherence - in multiple sclerosis patients is predicted by health-related quality of life and self-efficacy: a prospective web-based patient-centred study (CAIR study)
por: Jongen, Peter Joseph, et al.
Publicado: (2017)

Safety and Tolerability of Fesoterodine in Older Adult Patients with Overactive Bladder
por: Heesakkers, John, et al.
Publicado: (2022)

Antimuscarinics for neurogenic overactive bladder in multiple sclerosis: real-life data
por: Andretta, Elena, et al.
Publicado: (2022)

Solifenacin in Multiple Sclerosis Patients with Overactive Bladder: A Prospective Study
por: van Rey, Farida, et al.
Publicado: (2011)

Effectiveness of percutaneous tibial nerve stimulation in the treatment of overactive bladder syndrome
por: de Wall, Liesbeth L, et al.
Publicado: (2017)

Nerve sprouting and neurogenic inflammation characterize the neurogenic detrusor overactive bladder of patients no longer responsive to drug therapies
por: Traini, Chiara, et al.
Publicado: (2019)

Adaptive changes of telocytes in the urinary bladder of patients affected by neurogenic detrusor overactivity
por: Traini, Chiara, et al.
Publicado: (2017)

Urodynamic efficacy of fesoterodine for the treatment of neurogenic detrusor overactivity and/or low compliance bladder
por: Kaga, Kanya, et al.
Publicado: (2020)

Intensive social cognitive treatment (can do treatment) with participation of support partners in persons with relapsing remitting multiple sclerosis: observation of improved self-efficacy, quality of life, anxiety and depression 1 year later
por: Jongen, Peter Joseph, et al.
Publicado: (2016)

Differences in the Urinary Microbiome of Patients with Overactive Bladder Syndrome with and without Detrusor Overactivity on Urodynamic Measurements
por: Javan Balegh Marand, Aida, et al.
Publicado: (2023)

Botulinum Toxin in Neurogenic Detrusor Overactivity
por: D'Ancona, Carlos Arturo Levi, et al.
Publicado: (2012)

Onabotulinumtoxin A for Treating Overactive/Poor Compliant Bladders in Children and Adolescents with Neurogenic Bladder Secondary to Myelomeningocele
por: Marte, Antonio
Publicado: (2012)

Real-life patient experiences of TTNS in the treatment of overactive bladder syndrome
por: te Dorsthorst, Manon, et al.
Publicado: (2021)

Neurogenic overactive bladder in spinal cord injury and multiple sclerosis: role of onabotulinumtoxinA
por: Ethans, KD, et al.
Publicado: (2014)

The Interactive Web-Based Program MSmonitor for Self-Management and Multidisciplinary Care in Persons With Multiple Sclerosis: Quasi-Experimental Study of Short-Term Effects on Patient Empowerment
por: Jongen, Peter Joseph, et al.
Publicado: (2020)

Molecular Mechanism Operating in Animal Models of Neurogenic Detrusor Overactivity: A Systematic Review Focusing on Bladder Dysfunction of Neurogenic Origin
por: Ferreira, Ana, et al.
Publicado: (2023)

Improved self-efficacy in persons with relapsing remitting multiple sclerosis after an intensive social cognitive wellness program with participation of support partners: a 6-months observational study
por: Jongen, Peter Joseph, et al.
Publicado: (2014)

Clinical utility of neurostimulation devices in the treatment of overactive bladder: current perspectives
por: Janssen, Dick AW, et al.
Publicado: (2017)

Characterization of upper lamina propria interstitial cells in bladders from patients with neurogenic detrusor overactivity and bladder pain syndrome
por: Gevaert, Thomas, et al.
Publicado: (2011)

Korean Translation and Linguistic Validation of Urgency and Overactive Bladder Questionnaires
por: Kim, Seung-Ee, et al.
Publicado: (2020)

Dealing with complex overactive bladder syndrome patient profiles with focus on fesoterodine: in or out of the EAU guidelines?
por: Heesakkers, John, et al.
Publicado: (2017)

Targeting neurotrophin and nitric oxide signaling to treat spinal cord injury and associated neurogenic bladder overactivity
por: Ikeda, Youko, et al.
Publicado: (2022)

OnabotulinumtoxinA for the treatment of neurogenic detrusor overactivity in children
por: Austin, Paul F., et al.
Publicado: (2020)

Overactive bladder
por: Wallace, Karen M., et al.
Publicado: (2015)

Validation of the Arabic linguistic version of the Overactive Bladder Symptoms Score questionnaire
por: Elbaset, M. A., et al.
Publicado: (2019)

An intensive social cognitive program (can do treatment) in people with relapsing remitting multiple sclerosis and low disability: a randomized controlled trial protocol
por: Jongen, Peter Joseph, et al.
Publicado: (2016)

Transcutaneous Electrical Stimulation of the Abdomen, Ear, and Tibial Nerve Modulates Bladder Contraction in a Rat Detrusor Overactivity Model: A Pilot Study
por: Coolen, Rosa L., et al.
Publicado: (2023)

The Botulinum Treatment of Neurogenic Detrusor Overactivity: The Double-Face of the Neurotoxin
por: Traini, Chiara, et al.
Publicado: (2019)

Acute effect of sacral neuromodulation for treatment of detrusor overactivity on urodynamic parameters
por: Groenendijk, Ilse M., et al.
Publicado: (2019)

Two‐year safety and efficacy outcomes for the treatment of overactive bladder using a long‐lived rechargeable sacral neuromodulation system
por: Blok, Bertil, et al.
Publicado: (2020)

Validating 7-items Overactive Bladder Symptom Score (OABSS) through Arabic linguistic version
por: Sawaqed, Fadi, et al.
Publicado: (2021)

Neurogenic Bladder
por: Dorsher, Peter T., et al.
Publicado: (2012)

Erratum to: OnabotulinumtoxinA is Effective in Patients with Urinary Incontinence due to Neurogenic Detrusor Overactivity Regardless of Concomitant Anticholinergic Use or Neurologic Etiology
por: Ginsberg, David, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_rt049k31c41tcq74gp261325o1